Trastuzumab Deruxtecan

Evidence Level: L5 Predicted Indications: 50

Quick Overview

Item Value
Drug Name Trastuzumab Deruxtecan
DrugBank ID DB14962
Brand Names (EU) Enhertu
Evidence Level L5
Predicted Indications 50
Top Prediction Score 99.31%

Approved Indication (EMA)

Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low and HER2-ultralow breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic  hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine the

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 drug-induced osteoporosis 99.31% DL
2 severe nonproliferative diabetic retinopathy 98.92% DL
3 diabetic retinopathy 98.46% DL
4 bronchitis 98.00% DL
5 diabetic cataract 96.60% DL
6 chondroid hamartoma 95.98% DL
7 non-seminomatous lesion 95.98% DL
8 ductal or ductular proliferation 95.98% DL
9 bronchial adenomas/carcinoids childhood 95.98% DL
10 tumor of testis and paratestis 95.81% DL
11 thyroglossal duct cyst 95.77% DL
12 cystic neoplasm 95.69% DL
13 mesenchymoma 95.67% DL
14 benign neoplasm of tongue 95.60% DL
15 cervical neuroblastoma 95.56% DL
16 inner ear neoplasm 95.56% DL
17 indolent plasma cell myeloma 95.53% DL
18 epiglottis neoplasm 95.53% DL
19 benign neoplasm of floor of mouth 95.52% DL
20 hemorrhagic disease of newborn 95.51% DL

Showing top 20 of 50 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.